Pyxis Oncology Inc
NASDAQ:PYXS
Pyxis Oncology Inc
Cash from Financing Activities
Pyxis Oncology Inc
Cash from Financing Activities Peer Comparison
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Pyxis Oncology Inc
NASDAQ:PYXS
|
Cash from Financing Activities
$5.9m
|
CAGR 3-Years
429%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Financing Activities
-$17.2B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-17%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Financing Activities
-$5.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Financing Activities
$21B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
23%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Financing Activities
-$562.2m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Financing Activities
-$1.8B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-88%
|
CAGR 10-Years
N/A
|
See Also
What is Pyxis Oncology Inc's Cash from Financing Activities?
Cash from Financing Activities
5.9m
USD
Based on the financial report for Dec 31, 2023, Pyxis Oncology Inc's Cash from Financing Activities amounts to 5.9m USD.
What is Pyxis Oncology Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 3Y
429%
Over the last year, the Cash from Financing Activities growth was 3 194%. The average annual Cash from Financing Activities growth rates for Pyxis Oncology Inc have been 429% over the past three years .